Stockscreener 앱 받기
44.22
1.73%
0.75
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Awards Key Employee Stock Grants: 15,175 RSUs Distributed in Strategic Talent Acquisition - StockTitan
RARE Submits BLA To The FDA For Sanfilippo Syndrome Gene Therapy - Barchart
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy - Zacks Investment Research
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $88.00 Price Target at Wells Fargo & Company - MarketBeat
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts - Benzinga
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Geode Capital Management LLC - MarketBeat
Ultragenyx seeks FDA nod for Sanfilippo A gene therapy By Investing.com - Investing.com Canada
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome - GlobeNewswire
Ultragenyx Launches Pivotal Phase 3 Trial for Breakthrough Angelman Syndrome Treatment GTX-102 - StockTitan
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Ultragenyx seeks FDA nod for Sanfilippo A gene therapy - Investing.com
Ultragenyx Submits Biologics License Application to the - GlobeNewswire
Ultragenyx Seeks FDA Approval for Groundbreaking Sanfilippo Syndrome Gene Therapy - StockTitan
Ultragenyx Pharmaceutical Inc. Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) - Marketscreener.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
State Street Corp Has $147.99 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical's SWOT analysis: rare disease biotech stock at crossroads - Investing.com
Y Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Janus Henderson Group PLC Sells 35,200 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion - The Globe and Mail
Hypophosphatasia Market Expected to Experience Major Growth - openPR
Frazier Life Sciences Management L.P. Purchases 208,715 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
CDKL5 Deficiency Disorder Pipeline 2024: Clinical Trials - openPR
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Wellington Management Group LLP - MarketBeat
BNP Paribas Financial Markets Sells 38,641 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Opinion: What Accelerated Approval’s Naysayers Miss - BioSpace
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Jacobs Levy Equity Management Inc. - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Point72 Asset Management L.P. - MarketBeat
Point72 DIFC Ltd Has $806,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
(RARE) On The My Stocks Page - Stock Traders Daily
Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Australia
RTW Investments LP Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Possible Bearish Signals With Ultragenyx Pharmaceutical Insiders Disposing Stock - Simply Wall St
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Lessened by Cinctive Capital Management LP - MarketBeat
Bamco Inc. NY Purchases New Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Erste Asset Management GmbH Makes New Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Verition Fund Management LLC Reduces Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Cerity Partners LLC Invests $1.77 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Baker BROS. Advisors LP Has $87.55 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Capstone Investment Advisors LLC Purchases Shares of 13,089 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Vestal Point Capital LP Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Suvretta Capital Management LLC Sells 910,112 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Alkeon Capital Management LLC Boosts Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Acuta Capital Partners LLC Purchases New Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx to Participate in Investor Conferences in December - GlobeNewswire
Ultragenyx to Present at Three Major Healthcare Investor Conferences in December | RARE Stock News - StockTitan
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
CDKL5 Deficiency Disorder Market Revenue to Expand - openPR
Algert Global LLC Boosts Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Massachusetts Financial Services Co. MA Purchases 172,126 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Swiss National Bank Grows Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Holdings Boosted by Natixis Advisors LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Sells 87,626 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Top 10 startups in Rare Diseases in Bay Area, United States in Nov, 2024 - Tracxn
B. Metzler seel. Sohn & Co. Holding AG Takes $1.32 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):